Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1877 1
1885 1
1887 1
1888 2
1902 1
1964 1
1965 1
1969 1
1971 1
1975 1
1977 2
1978 3
1979 3
1980 1
1981 4
1982 8
1983 4
1984 4
1985 3
1986 2
1987 13
1988 6
1989 6
1990 5
1991 9
1992 7
1993 12
1994 10
1995 10
1996 13
1997 10
1998 5
1999 3
2000 11
2001 7
2002 7
2003 4
2004 3
2005 6
2006 10
2007 7
2008 10
2009 10
2010 17
2011 14
2012 11
2013 14
2014 10
2015 15
2016 18
2017 20
2018 16
2019 20
2020 21
2021 43
2022 33
2023 26
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Results by year

Filters applied: . Clear all
Page 1
Immunometabolism and natural killer cell responses.
O'Brien KL, Finlay DK. O'Brien KL, et al. Among authors: finlay dk. Nat Rev Immunol. 2019 May;19(5):282-290. doi: 10.1038/s41577-019-0139-2. Nat Rev Immunol. 2019. PMID: 30808985 Review.
FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells.
Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, Sangfelt O, Bradley LM, Wohlschlegel J, Rich JN, Spruck C. Shen JZ, et al. Among authors: finlay d. Cell. 2021 Jan 21;184(2):352-369.e23. doi: 10.1016/j.cell.2020.11.042. Epub 2020 Dec 23. Cell. 2021. PMID: 33357448 Free PMC article.
Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity.
Jenkins BJ, Blagih J, Ponce-Garcia FM, Canavan M, Gudgeon N, Eastham S, Hill D, Hanlon MM, Ma EH, Bishop EL, Rees A, Cronin JG, Jury EC, Dimeloe SK, Veale DJ, Thornton CA, Vousden KH, Finlay DK, Fearon U, Jones GW, Sinclair LV, Vincent EE, Jones N. Jenkins BJ, et al. Among authors: finlay dk. Cell Metab. 2023 Jul 11;35(7):1132-1146.e9. doi: 10.1016/j.cmet.2023.05.001. Epub 2023 May 24. Cell Metab. 2023. PMID: 37230079 Free article.
Metabolic reprogramming of natural killer cells in obesity limits antitumor responses.
Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K, Beyaz S, Tavakkoli A, Foley C, Donnelly R, O'Farrelly C, Raverdeau M, Vernon A, Pettee W, O'Shea D, Nikolajczyk BS, Mills KHG, Brenner MB, Finlay D, Lynch L. Michelet X, et al. Among authors: finlay d. Nat Immunol. 2018 Dec;19(12):1330-1340. doi: 10.1038/s41590-018-0251-7. Epub 2018 Nov 12. Nat Immunol. 2018. PMID: 30420624
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.
Viel S, Marçais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, Degouve S, Djebali S, Sanlaville A, Charrier E, Bienvenu J, Marie JC, Caux C, Marvel J, Town L, Huntington ND, Bartholin L, Finlay D, Smyth MJ, Walzer T. Viel S, et al. Among authors: finlay d. Sci Signal. 2016 Feb 16;9(415):ra19. doi: 10.1126/scisignal.aad1884. Sci Signal. 2016. PMID: 26884601
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer.
Slattery K, Woods E, Zaiatz-Bittencourt V, Marks S, Chew S, Conroy M, Goggin C, MacEochagain C, Kennedy J, Lucas S, Finlay DK, Gardiner CM. Slattery K, et al. Among authors: finlay dk. J Immunother Cancer. 2021 Feb;9(2):e002044. doi: 10.1136/jitc-2020-002044. J Immunother Cancer. 2021. PMID: 33568351 Free PMC article.
Glucose, glycolysis and lymphocyte responses.
Donnelly RP, Finlay DK. Donnelly RP, et al. Among authors: finlay dk. Mol Immunol. 2015 Dec;68(2 Pt C):513-9. doi: 10.1016/j.molimm.2015.07.034. Epub 2015 Aug 7. Mol Immunol. 2015. PMID: 26260211 Review.
Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.
Haney M, Vallée M, Fabre S, Collins Reed S, Zanese M, Campistron G, Arout CA, Foltin RW, Cooper ZD, Kearney-Ramos T, Metna M, Justinova Z, Schindler C, Hebert-Chatelain E, Bellocchio L, Cathala A, Bari A, Serrat R, Finlay DB, Caraci F, Redon B, Martín-García E, Busquets-Garcia A, Matias I, Levin FR, Felpin FX, Simon N, Cota D, Spampinato U, Maldonado R, Shaham Y, Glass M, Thomsen LL, Mengel H, Marsicano G, Monlezun S, Revest JM, Piazza PV. Haney M, et al. Among authors: finlay db. Nat Med. 2023 Jun;29(6):1487-1499. doi: 10.1038/s41591-023-02381-w. Epub 2023 Jun 8. Nat Med. 2023. PMID: 37291212 Free PMC article. Clinical Trial.
478 results